Is Eli Lilly And Company A Buy?

A few days ago, my colleague Cory Renauer wrote that there was a big week ahead for Eli Lilly and Company (NYSE: LLY). Cory was right. And we now know the outcomes of several of the big news stories for the drugmaker.Lilly and partner Incyte (NASDAQ: INCY) announced on Monday that an FDA advisory committee recommended approval of the 2 mg dose of baricitinib in treating rheumatoid arthritis, but not the 4 mg dose.

Topics:  cory renauer   company nyse   lly    incyte nasdaq   incy    fda   cory   lilly   eli lilly   big   mg   dose   
BING NEWS:
  • Eli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Call Transcript
    Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2024 Earnings Call. At this time all participants are in a listen-only mode. […]
    05/2/2024 - 3:41 am | View Link
  • Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise
    Eli Lilly's growth trajectory, strong new-product cycle, and pipeline make it a buy, with a potential fair value of $1,000 per share. Read more on LLY stock here.
    05/1/2024 - 6:10 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News